Actionable news
All posts from Actionable news
Actionable news in BRCD: Brocade Communications Systems, Inc.,

News Review: Amgen, Inc. (NASDAQ:AMGN), SanDisk Corporation (NASDAQ:SNDK), Brocade Communications Systems, Inc. (NASDAQ:BRCD), Stone Energy Corporation (NYSE:SGY)

On Friday, Amgen, Inc. (NASDAQ:AMGN)’s shares inclined 0.05% to $153.21.

Amgen (AMGN) declared the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for etelcalcetide (formerly AMG 416) for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on hemodialysis therapy. If approved, etelcalcetide will be the first calcimimetic agent that can be administered intravenously.

Etelcalcetide is a novel calcimimetic agent that suppresses the secretion of parathyroid hormone and is in clinical development for the treatment of SHPT in patients with CKD on hemodialysis. Etelcalcetide is administered intravenously three times per week at the end of each dialysis session. It acts by binding to and activating the calcium-sensing receptor on the parathyroid gland, thereby causing decreases in parathyroid hormone (PTH). Sustained elevations in PTH are known to be associated with noteworthy clinical consequences for patients with CKD.

The MAA submission for etelcalcetide comprises data from three Phase 3 studies, all of which met their primary endpoints, counting two pooled placebo-controlled trials in more than 1,000 patients and a head-to-head study evaluating etelcalcetide contrast with cinacalcet.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The companys principal products comprise Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients.

Brocade Communications Systems, Inc. (NASDAQ:BRCD)’s shares gained 0.68% to $10.33.

Brocade ( BRCD) declared that it will take part in Deutsche Bank 23rd Annual Leveraged...